<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">CEFTRIAXONE SODIUM</span><br/>(sef-try-ax'one)<br/><span class="topboxtradename">Rocephin<br/></span><b>Classifications:</b> <span class="classification">antiinfective</span>; <span class="classification">antibiotic</span>; <span class="classification">third-generation cephalosporin</span><br/><b>Prototype: </b>Cefotaxime sodium<br/><b>Pregnancy Category: </b>B<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>250 mg, 500 mg, 1 g, 2 g injection</p>
<h1><a name="action">Actions</a></h1>
<p>Semisynthetic third-generation cephalosporin antibiotic. Preferentially binds to one or more of the penicillin-binding proteins
         (PBP) located on cell walls of susceptible organisms. This inhibits third and final stage of bacterial cell wall synthesis,
         thus killing the bacterium.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p> Effectively treats bone and joint infections, gonorrhea and intra-abdominal infections, meningitis and lower respiratory
         tract infections, otitis media, pelvic inflammatory disease, <i>Proteus</i> infections, septicemia, skin and soft tissue infections, urinary tract infections, and is used for surgical prophylaxis,
         reducing or eliminating infection.
      </p>
<h1><a name="uses">Uses</a></h1>
<p>Infections caused by susceptible organisms in lower respiratory tract, skin and skin structures, urinary tract, bones and
         joints; also intra-abdominal infections, pelvic inflammatory disease, uncomplicated gonorrhea, meningitis, and surgical prophylaxis.
      </p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Hypersensitivity to cephalosporins and related antibiotics; pregnancy (category B).</p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Lactation.</p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Moderate to Severe Infections</span><br/><span class="rdage">Adult:</span> <span class="rdroute">IV/IM</span> 12 g q1224h (max: 4 g/d)<br/><span class="rdage">Child:</span> <span class="rdroute">IV/IM</span> 5075 mg/kg/d in 2 divided doses (max: 2 g/d)<br/><br/><span class="indicationtitle">Meningitis</span><br/><span class="rdage">Adult:</span> <span class="rdroute">IV/IM</span> 2 g q12h<br/><span class="rdage">Child:</span> <span class="rdroute">IV/IM</span> 75 mg/kg loading dose, then 100 mg/kg/d in 2 divided doses (max: 4 g/d)<br/><br/><span class="indicationtitle">Surgical Prophylaxis</span><br/><span class="rdage">Adult:</span> <span class="rdroute">IV/IM</span> 1 g 30120 min before surgery<br/><br/><span class="indicationtitle">Uncomplicated Gonorrhea</span><br/><span class="rdage">Adult:</span> <span class="rdroute">IM</span> 250 mg as single dose<br/><span class="rdage">Child:</span> <span class="rdroute">IM</span> 125 mg as single dose<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Intramuscular</span><br/><ul>
<li>Reconstitute the 1 g or 2 g vial by adding 2.1 mL or 4.2 mL, respectively, of sterile water for injection. Yields 3.50 mg/mL.
            See manufacturer's directions for other dilutions.
         </li>
<li>Give deep IM into a large muscle.</li>
</ul>
<table cellpadding="4" cellspacing="0" class="ivbox" width="100%">
<tr>
<td><span class="ivtitle">Intravenous</span><ul>
<li>IV administration to infants and children: Verify correct IV concentration and rate of infusion with physician.</li>
</ul>
<p><span class="routemethod">PREPARE:</span> <span class="methodtype">Intermittent:</span> Reconstitute each 250 mg with 2.4 mL of sterile water, D5W, NS, or D5/NS to yield 100 mg/mL. Further dilute with 50100
                  mL of the selected IV solution.  
               </p>
<p><span class="routemethod">ADMINISTER:</span> <span class="methodtype"> Intermittent:</span>  Give over 30 min.  
               </p>
<p><span class="routemethod">INCOMPATIBILITIES</span> <span class="incompattype"> Solution/additive:</span>
<span class="classification">aminoglycosides</span>, <b>aminophylline,</b>
<b>clindamycin,</b>
<b>lidocaine,</b>
<b>metronidazole,</b>
<b>theo- phylline.</b>
<span class="incompattype"> Y-site:</span>
<b>Amiodarone,</b>
<span class="classification">aminoglycosides,</span>
<b>amphotericin B cholesteryl complex,</b>
<b>amsacrine,</b>
<b>azithromycin,</b>
<b>azithromycin,</b>
<b>fluconazole,</b>
<b>filgrastim,</b>
<b>labetalol,</b>
<b>pentamidine,</b>
<b>vancomycin,</b>
<b>vinorelbine.</b>
</p>
</td>
</tr>
</table>
<ul>
<li>Protect sterile powder from light. Store at 15°25° C (59°77° F). Reconstituted solutions:
            diluent, concentration of solutions are determinants of stability. See manufacturer's instructions for storage.
         </li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead"> Body as a Whole:</span> Pruritus, fever, chills, pain, induration at IM injection site; phlebitis (IV site). <span class="typehead">GI:</span>
<span class="speceff-common">Diarrhea,</span> abdominal cramps, <span class="speceff-life">pseudomembranous colitis</span>, biliary sludge. <span class="typehead">Urogenital:</span> Genital pruritus; moniliasis. 
      <h1><a name="dtintefer">Diagnostic Test Interference</a></h1>
<p>Causes prolonged <span class="alt">PT/INR</span> during therapy.
      </p>
<h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span>
<b>Probenecid</b> decreases renal elimination of ceftriaxone; <b>alcohol</b> produces disulfiram reaction. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Peak:</span> 1.54 h after IM; immediately after IV infusion. <span class="typehead">Distribution:</span> Widely distributed in body tissues and fluids; good CNS penetration, especially with inflamed meninges; crosses placenta. <span class="typehead">Metabolism:</span> Not metabolized. <span class="typehead">Elimination:</span> 3365% excreted unchanged in urine; also excreted in bile; small amount excreted in breast milk. <span class="typehead">Half-Life:</span> 510 h. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Determine history of hypersensitivity reactions to cephalosporins and penicillins and history of other allergies, particularly
            to drugs, before therapy is initiated.
         </li>
<li>Lab tests: Perform culture and sensitivity tests before initiation of therapy and periodically during therapy. Dosage may
            be started pending test results. Periodic coagulation studies (PT and INR) should be done.
         </li>
<li>Inspect injection sites for induration and inflammation. Rotate sites. Note IV injection sites for signs of phlebitis (redness,
            swelling, pain).
         </li>
<li>Monitor for manifestations of hypersensitivity (see Appendix F). Report their appearance promptly and discontinue drug.</li>
<li>Watch for and report signs: petechiae, ecchymotic areas, epistaxis, or any unexplained bleeding. Ceftriaxone appears to alter
            vitamin Kproducing gut bacteria; therefore, hypoprothrombinemic bleeding may occur.
         </li>
<li>Check for fever if diarrhea occurs: Report both promptly. The incidence of antibiotic-produced pseudomembranous colitis (see
            Appendix F) is higher than with most cephalosporins. Most vulnerable patients: chronically ill or debilitated older adult
            patients undergoing abdominal surgery.
         </li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Report any signs of bleeding.</li>
<li>Report loose stools or diarrhea promptly.</li>
<li>Do not breast feed while taking this drug without consulting physician.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>